Wounds and Injuries

All Conditions

Blood and Lymph Conditions

Diseases and Abnormalities at or Before Birth

Symptoms and General Pathology

Nervous System Diseases

Rare Diseases

Burns

Anemia, Sickle Cell

Anemia

Pain

Breakthrough Pain

Hemolysis

Anemia, Hemolytic

Anemia, Hemolytic, Congenital

Hematologic Diseases

Hemoglobinopathies

Genetic Diseases, Inborn

Neurologic Manifestations

Sickle Cell Anemia

Adjuvants, Anesthesia

Analgesics

Central Nervous System Depressants

All Drugs and Chemicals

Anticoagulants

Other Dietary Supplements

Fentanyl

Analgesics, Opioid

Citric Acid

Sodium Citrate

Narcotics

Anesthetics

Anesthetics, Intravenous

Anesthetics, General

Citrate

ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC])

John Messina

The objective of the study is to monitor the safety (adverse event data) of longer-term use of ACTIQ (Oral Transmucosal Fentanyl Citrate \[OTFC\]) treatment in children with pain associated with cancer, sickle cell disease, or severe burns and breakthrough pain (BTP) who are receiving around the clock (ATC) opioid therapy.

Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain

A 4-week, Open-Label Extension Study of ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC]) Treatment for Opioid-Tolerant Children and Adolescents With Breakthrough Pain

Cephalon

Musculoskeletal Diseases

Skin and Connective Tissue Diseases

Immune System Diseases

Arthritis

Chronic Pain

Arthritis, Rheumatoid

Arthritis, Juvenile

Chronic Graft Versus Host Disease

Oxymorphone

oxymorphone IR

The purpose of this study is to evaluate the effectiveness, tolerability, and safety of oxymorphone immediate release (IR) oral liquid as an analgesic in pediatric subjects having severe to moderate chronic pain.

Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects

AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTER EFFECTIVENESS, SAFETY AND TOLERABILITY STUDY OF OXYMORPHONE HCl IMMEDIATE-RELEASE ORAL LIQUID IN OPIOID-TOLERANT PEDIATRIC SUBJECTS WITH CHRONIC PAIN REQUIRING AN AROUND THE CLOCK OPIOID

Endo Pharmaceuticals

Sr. Director CR & D

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain	NCT00236093	Pain Cancer Sickle Cell Ane... Severe Burns	ACTIQ (Oral Tra...	3 Years - 15 Years	Teva Branded Pharmaceutical Products R&D, Inc.
Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain	NCT00236093	Pain Cancer Sickle Cell Ane... Severe Burns	ACTIQ (Oral Tra...	3 Years - 15 Years	Teva Branded Pharmaceutical Products R&D, Inc.
Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects	NCT01206907	Chronic Pain	oxymorphone IR	2 Years - 6 Years	Endo Pharmaceuticals

Spots Global Cancer Trial Database for sickle cell anemia